Phase 2
Completed N=71
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Source: ClinicalTrials.gov NCT00423332 ↗Enrolled (actual)
71
Serious AEs
21.7%
Results posted
Sep 2012
Primary outcomePrimary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline
Summary
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change From Baseline in Tumour Size at 12 Weeks |
-19.47; 19.65 | — |
| SECONDARY Best Percentage Change From Baseline in Tumour Size During the Study |
-26.90; 1.09 | — |
| SECONDARY Duration of Response |
18.595; 11.1 | — |
| SECONDARY Progression Free Survival |
12.1; 2.76 | — |
| SECONDARY Objective Tumour Response at 12 Weeks |
11; 0 | — |
| SECONDARY Best Objective Tumour Response |
18; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmation of metastatic or recurrent renal cell carcinoma
Exclusion Criteria
- Certain types of previous anti-cancer therapy for Renal Cell Carcinoma
- Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes
- Patients with a history of poorly controlled high blood pressure
Data sourced from ClinicalTrials.gov (NCT00423332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.